Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-07T14:25:42.670Z Has data issue: false hasContentIssue false

Policy brief on improving access to artemisinin-based combination therapies for malaria in Mozambique

Published online by Cambridge University Press:  15 April 2010

Francisco Mbofana
Affiliation:
Instituto Nacional de Saúde
Gertrudes Machatine
Affiliation:
Ministry of Health, Maputo
Celeste Moreira
Affiliation:
Health Woman and Social Welfare Services, Matola
Rights & Permissions [Opens in a new window]

Extract

Malaria is a major cause of morbidity and mortality in Mozambique. Approximately 6 million cases are reported each year. Malaria accounts for approximately 40 percent of all outpatient visits and 60 percent of pediatric hospital admissions. It is the leading cause of death among children admitted to pediatric services. Malaria transmission takes place year round with a seasonal peak extending from December to April. More than 18.5 million people in Mozambique are considered to be at-risk of malaria, including an estimated 3.6 million children less than 5 years old and almost 1 million pregnant women (13). The Presidential Malaria Initiative (PMI) -supported Malaria Indicator Survey, conducted in 2007, found the national prevalence of malaria parasitemia among children 6 to 59 months old to be 38.5 percent, with a range by province from 60.4 percent in Nampula to less than 10 percent in Maputo. Among pregnant women, the parasite prevalence was 16.3 percent, with 30.1 percent of women in their first pregnancy demonstrating parasites on blood slides (11).

Information

Type
THEME SECTION: OPTIONS FOR IMPROVING MALARIA TREATMENT
Copyright
Copyright © Cambridge University Press 2010
Figure 0

Table 1. Policy options

Figure 1

Table 2. Implementation of the Policy Options